ArticleJournal of managed care & specialty pharmacy2026
Clinical and economic burden of chronic kidney disease in Medicare Fee-for-Service beneficiaries with and without comorbid type 2 diabetes and heart failure: A retrospective cohort study.
Article in Journal of managed care & specialty pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic kidney disease (CKD) is common in older adults and is often associated with type 2 diabetes (T2DM) and heart failure (HF). However, little is known about the burden of newly diagnosed CKD in Medicare Fee-for-Service (FFS) beneficiaries, including those with comorbid T2DM or HF.
objectiveTo quantify the clinical and economic burden of CKD in Medicare FFS beneficiaries, including those with comorbid T2DM or HF.
methodsIn this retrospective cohort study using 100% Medicare FFS claims data (Parts A, B, D) from 2014 to 2022, beneficiaries with incident CKD (based on a diagnosis code on 2 distinct dates) from January 1, 2015, to December 31, 2021, were included; index date was the date of earliest CKD diagnosis. Beneficiaries with a diagnosis of CKD, acute kidney injury, dialysis, kidney transplantation, or a claim for any condition other than T2DM that could cause kidney disease during a 365-day baseline period prior to index date were excluded. Beneficiaries with CKD were categorized into 4 mutually exclusive cohorts: CKD-only; CKD+HF; CKD+T2DM; and CKD+HF+T2DM based on claims during the baseline period. Clinical burden was measured as prevalence at baseline and incidence of key clinical outcomes at 12 months of follow-up. Economic burden was measured as all-cause and CKD-related health care resource utilization (HCRU) and inflation-adjusted costs in the baseline period and at 12 months of follow-up.
resultsThe overall cohort consisted of 2,260,075 patients, mean (SD) age 78.3 (7.7) years (56.5% CKD-only; 7.2% CKD+HF; 30.9% CKD+T2DM; and 5.4% CKD+HF+T2DM). The CKD+HF+T2DM cohort generally exhibited the highest incidence of clinical outcomes within 12 months. Cohorts with HF had higher HCRU across all claim types in both the baseline and 12-month follow-up periods compared with the other cohorts (
conclusionsOlder adults with a new diagnosis of CKD experienced considerable clinical and economic burden, and presence of T2DM and HF was associated with larger burden. All-cause mean total costs at 12 months after a new diagnosis of CKD ranged from $24,180 for the CKD-only cohort to $54,477 for the CKD+HF+T2DM cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.